Dr. Druley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4515 McKinley Avenue
Campus Box 8510
Saint Louis, MO 63110- Is this information wrong?
Summary
- Todd Druley, MD, PhD is the Chief Medical Officer of ANGLE Biosciences. He received his medical and graduate degrees from University of Illinois before moving to Washington University School of Medicine in St. Louis to study pediatric oncology as a physician-scientist. He is experienced in molecular diagnostics, cancer genetics, genetic variation, and population genetics.
Education & Training
- Washington University/B-JH/SLCH ConsortiumFellowship, Pediatric Hematology/Oncology, 2005 - 2008
- Washington University School of MedicinePediatric, 2003 - 2005
- Washington University School of MedicinePediatric, 2002 - 2003
- University of Illinois College of MedicineM.D./Ph.D, Training Program, 1994 - 2002
- University of Illinois College of MedicineClass of 2002, MD, PhD
- University of Illinois at ChicagoMD, PhD, Medicine, Molecular Genetics, 2002
- University of Illinois at Urbana-ChampaignBS, Cell and Structural Biology, 1994
Certifications & Licensure
- MO State Medical License 2008 - 2025
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Elected Member American Society of Clinical Investigators, 2019
- Hyundai Quantum Award Hyundai Hope on Wheels, 2018
- Scholar Award Leukemia & Lymphoma Society, 2018
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsA study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.Cai, S., Huang, Y., Lance, J., Mao, H., Dunbar, A., McNulty, S., Druley, T., Li, Y., Baer, M., Stock, W., Kovacsovics, T., Blum, W., Schiller, G., Olin, R., Foran, J.,...> ;Blood Advances. 2024 Jan 23
- 3 citationsClonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction.Jesse D Cochran, Yoshimitsu Yura, Mark C Thel, Heather Doviak, Ariel H Polizio, Yuka Arai, Yohei Arai, Keita Horitani, Eunbee Park, Nicholas W Chavkin, Anupreet Kour, ...> ;Circulation. 2023 Oct 10
- 4 citationsClonal hematopoiesis in survivors of childhood cancer.Novetsky Friedman, D., Chan, I., Moskowitz, C., Li, S., Turner, K., Liu, J., Bouvier, N., Walsh, M., Spitzer, B., Kung, A., Berger, M., Cooper, M., Pusic, I., Uy, G., ...> ;Blood Advances. 2023 Aug 8
- Join now to see all
Journal Articles
- Mechanistic analysis of the multidrug transporter P-glycoprotein using a conformation-sensitive antibody.Druley TE, Ruth AC, Stein WD and Roninson IB, Proc. Amer. Assn. Cancer Res. 41: 762, 2000
- Detection of rare genomic variants from pooled sequencing using SPLINTER.Vallania FLM, Ramos E, Cresci S, Mitra RD, Druley TE, J. of Visualized Experiments. 64: e3943, DOI: 10.3791/3943
- Traditional and targeted exome sequencing reveals common, rare and novel deleterious variants in RET signaling complex in a cohort of living US patients with urinary t...Chatterjee R, Ramos E, Hoffman M, VanWinkle J, Martin D, Davis TK, Hoshi M, Hmiel SP, Beck A, Hruska K, Coplen D, Liapis H, Mitra R, Druley T, Austin P, Jain S, Human Genetics. “PMC Journal – In Process”
Abstracts/Posters
- High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-InductionTodd E Druley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Generation, Characterization and Pre-Clinical Drug Evaluation of Patient-Derived Xenograft Models of Pediatric Down Syndrome AMLTodd E Druley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Authored Content
- Minimal Residual Disease Testing - Current Innovations and Future DirectionsNovember 2018
Press Mentions
- Single-Cell Resolved Imaging Reveals Intra-Tumor Heterogeneity in Glycolysis, Transitions Between Metabolic States, and Their Regulatory MechanismsFebruary 16th, 2021
- Novel Mutations in Stem Cells of Young Donors Can Be Passed to RecipientsJanuary 20th, 2020
- Previously Unseen Mutations in Stem Cells of Young Donors Can Be Passed to Recipients, Study FindsJanuary 15th, 2020
- Join now to see all
Professional Memberships
- Member
- American Association for Cancer Research - AACRMember
- American Society for Pediatric Hematology and Oncology - ASPHOMember
- American Society of Clinical Investigators - ASCIMember
Industry Relationships
- Chief Medical Officer, ArcherDX, Inc2019 - Present
- Co-Inventor of RareSeq, Canopy BiosciencesDisclosure: The RareSeq method was developed as error-corrected sequencing (ECS) by the Druley lab. A patent held by Washington Univ is pending and the technology has been licensed by Canopy Biosciences.2018 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: